Belén Martínez Castedo

[Noelia Tarazona @TarazonaNoelia]

💣 When used at a single timepoint, tumor-informed and tumor-agnostic ctDNA🩸assays show similar performance; however, with serial monitoring, tumor-informed assays clearly outperform tumor-agnostic approaches in sensitivity for recurrence❗️

🔗https://t.co/hmUtEu9H9n

🩸🩸🩸🩸

[Noelia Tarazona @TarazonaNoelia]

🤝An international collaboration with @aparna1024 and our CRC team @incliva_iis @GVAsanitat

[Noelia Tarazona @TarazonaNoelia]

🔥 We got the cover of the June issue of @NatureCancer with our paper! 🌟 A huge honor and a recognition of the team’s hard work.

🔗 https://t.co/IyvDXz7vC5

📄 See https://t.co/l79etJ9lgH

[Noelia Tarazona @TarazonaNoelia]

💥Proud of our team for presenting cutting-edge work on ctDNA🩸and tumor-immune profiling in CRC at #EACR2025!

🔬From resistance mechanisms to new immunotherapy strategies - science made in Valencia @incliva_iis 🇪🇸✨
🔝@_belenmartinez @dgcamblor @GarciaMicoB

[Noelia Tarazona @TarazonaNoelia]

Este TEAM lo ha hecho posible❤️👇, a la guía de mi mentor Andrés Cervantes y al apoyo de becas @_SEOM @GrupoTTD @SaludISCIII

[Noelia Tarazona @TarazonaNoelia]

🔥 So proud of @KokeMartin @_belenmartinez @dgcamblor presenting their work at the X Liquid Biopsy Symposium🩸Their research on ctDNA and epigenomics in pancreatic and CRC showcases their talent and dedication. 👏Congratulations on pushing science forward! #SantiagoLiquidBiopsy

[Excelencia Oncología Molecular @ExcelenciaOnco1]

La biopsia líquida revoluciona el manejo del cáncer, ofreciendo diagnóstico temprano, monitoreo en tiempo real y tratamientos personalizados.

#BiopsiaLíquida #Oncología

No te pierdas la noticia ⬇️ @CIBERONC @TarazonaNoelia

https://t.co/ipcJp1aEMn

[International Society of Liquid Biopsy @isliquidbiopsy]

Minimal residual disease in colorectal cancer: Tumor-informed vs tumor-agnostic approaches 📊

🔍 Key Insights:

✅ctDNA enhances risk stratification & adjuvant therapy guidance.
✅Tumor-informed strategies show higher sensitivity. 🎯
✅Tumor-agnostic methods offer broader clinical applicability. 🌐
✅Emerging technologies like fragmentomics & multi-omics improve precision.

🔗 Read more here: https://t.co/8LXJjE3Rvo

@ChristianRolfo @ElJanLe @DrYukselUrun @UmbertoMalapel1 @OncoAlert @drgandara
@MJOSESERRANO19

[Noelia Tarazona @TarazonaNoelia]

🧠My thoughts after this review by @_belenmartinez @dgcamblor on ctDNA analysis:

* Tumor-informed assays = higher sensitivity but need tumor tissue.

* Tumor-agnostic = broader use, lower sensitivity. 💡Multi-omics integration is key.

[Noelia Tarazona @TarazonaNoelia]

🚨 Just out in @Annals_Oncology!

🌊 Dive into the latest on liquid biopsy for colorectal cancer🩸: What’s the best approach to monitor ctDNA? Tumor-informed vs. tumor-agnostic strategies for minimal residual disease detection.

📄Read here: [https://t.co/qSk5oJbUXi]